Policosanol for cholesterol: the Cuban trials that no one could reproduce

Policosanol is one of the cleanest examples of regional trial bias in supplement science. Cuban trials reported LDL reductions rivaling low-dose statins, but every well-controlled independent replication outside Cuba — across Germany, Spain, Canada, the US, and South Africa — has found essentially no lipid-lowering effect. The supplement category continues to market the original Cuban numbers.

What policosanol actually is

Policosanol is a mixture of long-chain primary aliphatic alcohols, predominantly octacosanol, derived originally from sugarcane wax. The proprietary Cuban preparation contains a specific ratio of C24–C34 alcohols. Other commercial sources include rice bran wax, beeswax, and wheat germ, with varying alcohol profiles. The 'octacosanol' supplements sold for athletic endurance are essentially the same chemistry.

The Cuban trial dossier

Between 1991 and 2005 the Center for Natural Products in Havana published dozens of randomized trials reporting that policosanol 5–20 mg/day reduced LDL cholesterol by 18–30% and raised HDL by 5–15% in hypercholesterolemic patients [1][2]. Effect sizes approached those of statins. Trials were essentially uniformly positive, reasonably sized, and produced an attractive marketing narrative.

The independent replications

When German investigators conducted an independent randomized trial of policosanol 10, 20, 40, or 80 mg/day in 143 patients with hypercholesterolemia or combined hyperlipidemia, the result was unambiguous: no significant change in LDL, HDL, total cholesterol, triglycerides, or apolipoprotein levels at any dose versus placebo [3]. The trial was rigorously double-blinded and used the same indications that the Cuban trials had used.

The meta-analysis

A 2010 meta-analysis split the literature explicitly by region [4]. Cuban-conducted trials produced a pooled LDL reduction of about 24%; non-Cuban trials produced a pooled reduction of about 2%, not statistically different from zero. The geographic divide explained nearly all of the heterogeneity. The most plausible interpretations are systematic flaws in the Cuban trial methodology, undisclosed methodological differences, or selective publication.

Endothelial and platelet effects

A handful of small non-Cuban trials have reported modest improvements in platelet aggregation and flow-mediated dilation with policosanol, though again at smaller magnitude than the original Cuban reports. The clinical significance of these findings is unclear, and they do not translate into the cholesterol or cardiovascular event reductions the supplement is marketed for.

Athletic 'octacosanol'

Octacosanol-enriched policosanol supplements are also sold for endurance and recovery. The trials are small and inconsistent; the effect, if any, is smaller than that of caffeine, nitrate, or creatine. There is no compelling efficacy case for athletic use.

Safety

Policosanol is well tolerated at doses up to 80 mg/day. Adverse events in trials are mild and similar to placebo. Theoretical platelet inhibition argues for caution with anticoagulants, but clinical bleeding has been very rare. There are no significant drug interactions of note.

The bottom line

Policosanol has essentially no reproducible cholesterol-lowering effect in well-controlled independent trials. The widely cited efficacy numbers come from a single geographic source that no one has been able to replicate. Patients seeking LDL reduction with non-statin options should look to soluble fiber, plant sterols, red yeast rice (with caution), or bempedoic acid — not policosanol.